Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$7.82 USD

7.82
2,215,062

-0.26 (-3.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.81 -0.01 (-0.13%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for IRWD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Ironwood Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 92 657 621 364 178
Receivables 129 115 114 122 117
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 1
Other Current Assets 12 8 10 9 11
Total Current Assets 233 781 745 496 307
Net Property & Equipment 6 6 8 9 12
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 15 24 23 33
Deferred Charges 212 284 333 0 0
Intangibles 4 0 0 0 1
Deposits & Other Assets 4 1 1 14 32
Total Assets 471 1,101 1,127 559 403
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 8 0 1 1 5
Current Portion Long-Term Debt 200 0 117 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 66 22 39 28 33
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 1 0 1
Total Current Liabilities 276 26 162 32 41
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 198 0 337 430 408
Long-Term Debt 300 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 28 406 4 14 25
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 817 448 521 497 496
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,355 1,349 1,543 1,529 1,479
Retained Earnings -1,699 -696 -938 -1,466 -1,572
Other Equity -3 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -346 652 606 63 -93
Total Liabilities & Shareholder's Equity 471 1,101 1,127 559 403
Total Common Equity -346 652 606 63 -93
Shares Outstanding 156.30 154.00 162.00 160.60 157.50
Book Value Per Share -2.22 4.24 3.74 0.39 -0.59

Fiscal Year End for Ironwood Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 92 111 176 742
Receivables NA 129 125 119 116
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 12 18 23 9
Total Current Assets NA 233 254 318 866
Net Property & Equipment NA 6 6 6 6
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 212 244 258 268
Intangibles NA 4 4 4 0
Deposits & Other Assets NA 4 4 4 1
Total Assets NA 471 524 603 1,155
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 8 5 4 0
Current Portion Long-Term Debt NA 200 0 199 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 66 73 100 21
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 199 0 0
Total Current Liabilities NA 276 281 305 24
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 198 198 198 0
Long-Term Debt NA 300 325 400 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 31 31 408
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 817 850 950 448
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,355 1,375 1,367 1,357
Retained Earnings NA -1,699 -1,698 -1,713 -651
Other Equity NA -3 -3 -1 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -346 -326 -347 707
Total Liabilities & Shareholder's Equity NA 471 524 603 1,155
Total Common Equity 0 -346 -326 -347 707
Shares Outstanding 156.50 156.30 156.10 156.00 155.30
Book Value Per Share 0.00 -2.22 -2.09 -2.22 4.55